The Valley Desk

ArticleAlzheimer's & dementia : the journal of the Alzheimer's AssociationPublished

FDA-approved carbonic anhydrase inhibitors reduce amyloid β pathology and improve cognition, by ameliorating cerebrovascular health and glial fitness

Read the publication ↗ Open access copy ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Lewis Katz School of Medicine, Temple University. Affiliation source

Publication record

Type
Article
Venue
Alzheimer's & dementia : the journal of the Alzheimer's Association
Published
Subject terms
Endothelial Cells; Animals; Humans; Mice; Cerebral Amyloid Angiopathy; Alzheimer Disease; Carbonic Anhydrase Inhibitors; Cognition; United States; Amyloid beta-Peptides; Alzheimer's disease; Astrocytes
PubMed ID
37186121
PubMed Central ID
PMC10600328
Added to directory
Source checked

Report a correction or request removal